Ailux Partners with Lilly to Propel Bispecific Antibody Innovations in Drug Development

Ailux Collaborates with Eli Lilly for Advanced Drug Development

In an exciting development for the biopharmaceutical industry, Ailux, a subsidiary of XtalPi, and Eli Lilly have announced a strategic partnership aimed at accelerating the discovery and development of bispecific antibodies. This collaboration leverages Ailux's innovative AI-powered platform to promote the treatment of various diseases, ensuring faster and more efficient drug development processes.

Strengthening Bonds in Biotherapeutics

Ailux has quickly made a name for itself in the sphere of AI-driven biologics, and this partnership is yet another testament to its growing influence in the sector. Lilly has recognized Ailux’s prowess in the field of bispecific antibody technology, establishing this collaboration as an extension of their long-standing relationship.

The agreement allows Lilly to utilize Ailux's cutting-edge bispecific antibody engineering platform. This platform is distinguished by its sophisticated integration of structural modeling, generative design, and developability analytics. The prime objective is to deliver novel therapeutic constructs that boast optimal efficacy and drug-like properties.

According to Jian Ma, PhD, the CEO and co-founder of XtalPi, Lilly's expansion into biologics using their AI-enabled platforms validates the exceptional capabilities of Ailux.